Elanco Animal Health Incorporated
Financials
Valuation Metrics
Elanco Animal Health Incorporated's Market Cap is $12.03B. At end of 2025 it was $11.24B. Ranked #829 of 3,116 in US market (top 27%), #574 of 1,644 on NYSE (top 35%), #39 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 15%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $12.03B | US#829/3,116 Sec#39/265 |
| Revenue | $5.02B | US#880/3,116 Sec#26/265 |
| Net Income | $-199M | US—/3,116 Sec—/265 |
| Total Assets | $13.56B | US#818/3,116 Sec#25/265 |
| Net Assets | $6.59B | US#571/3,116 Sec#23/265 |
| Employees | 9,400 | US#891/3,116 Sec#26/265 |
| Value | ||
| P/B | 1.83x | US#1,096/3,116 Sec#48/265 |
| P/S | 2.40x | US#1,416/3,116 Sec#36/265 |
| EV/EBITDA | 19.92x | US#1,843/3,116 Sec#49/265 |
| FCF Yield | 3.15% | US#1,746/3,116 Sec#52/265 |
| Profitability | ||
| ROE | -3.02% | US#2,207/3,116 Sec#72/265 |
| ROA | -1.47% | US#2,337/3,116 Sec#78/265 |
| Op. Margin | 9.20% | US#1,643/3,116 Sec#64/265 |
| Revenue Growth | 11.95% | US#1,090/3,116 Sec#89/265 |
| Earnings Growth | -145.85% | US#1,894/3,116 Sec#57/265 |
| Financial Health | ||
| Debt Ratio | 105.84% | US#1,140/3,116 Sec#164/265 |
| Total Debt | $3.92B | US#806/3,116 Sec#27/265 |
| FCF | $379M | US#1,028/3,116 Sec#36/265 |
| Cash | $530M | US#1,035/3,116 Sec#56/265 |
| Current Ratio | 2.05x | US#1,196/3,116 Sec#218/265 |
| Net Debt/EBITDA | 4.38x | US#1,915/3,116 Sec#70/265 |
| Performance | ||
| 1Y Return | 8.74% | US#1,731/3,116 Sec#145/265 |
| 1M Return | 8.79% | US#1,556/3,116 Sec#100/265 |
| From 52W High | -13.92% | US#1,357/3,116 Sec#73/265 |
| 1Y MDD | -26.23% | US#1,033/3,116 Sec#49/265 |
| Trading | ||
| Volume | 5,524,520 shares | US#706/3,116 Sec#59/265 |
| Trading Value | $132M | US#1,157/3,116 Sec#75/265 |
| Per Share | ||
| EPS | $-0.40 | US—/3,116 Sec—/265 |
| BPS | $13.19 | US#1,628/3,116 Sec#52/265 |
Company Info
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.